Hologic, Inc. (NASDAQ:HOLX) Stock Position Decreased by M&T Bank Corp

M&T Bank Corp decreased its position in Hologic, Inc. (NASDAQ:HOLXFree Report) by 14.8% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 26,483 shares of the medical equipment provider’s stock after selling 4,585 shares during the quarter. M&T Bank Corp’s holdings in Hologic were worth $1,892,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Nordea Investment Management AB increased its stake in shares of Hologic by 4.5% during the 3rd quarter. Nordea Investment Management AB now owns 1,616,999 shares of the medical equipment provider’s stock worth $113,077,000 after purchasing an additional 69,494 shares during the last quarter. Louisiana State Employees Retirement System acquired a new stake in shares of Hologic in the fourth quarter worth about $1,057,000. Pathstone Family Office LLC boosted its stake in shares of Hologic by 96.0% during the 3rd quarter. Pathstone Family Office LLC now owns 9,272 shares of the medical equipment provider’s stock worth $643,000 after acquiring an additional 4,542 shares in the last quarter. Ontario Teachers Pension Plan Board raised its stake in shares of Hologic by 186.7% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 38,404 shares of the medical equipment provider’s stock valued at $2,665,000 after acquiring an additional 25,010 shares in the last quarter. Finally, Natixis Advisors L.P. lifted its stake in shares of Hologic by 33.5% in the fourth quarter. Natixis Advisors L.P. now owns 258,736 shares of the medical equipment provider’s stock worth $18,486,000 after buying an additional 64,968 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling

In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at $119,802.12. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, Director Charles J. Dockendorff sold 1,465 shares of the company’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the transaction, the director now owns 1,572 shares in the company, valued at $119,802.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Scott T. Garrett sold 16,441 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The disclosure for this sale can be found here. 1.75% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on HOLX. Argus upped their price objective on shares of Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $90.00 price target on shares of Hologic in a research report on Friday, May 3rd. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research note on Friday, February 2nd. Finally, JPMorgan Chase & Co. increased their target price on shares of Hologic from $85.00 to $91.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.60.

Read Our Latest Stock Report on Hologic

Hologic Price Performance

HOLX opened at $75.75 on Friday. The company has a fifty day moving average price of $76.24 and a two-hundred day moving average price of $73.24. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97. The firm has a market capitalization of $17.68 billion, a PE ratio of 38.65, a P/E/G ratio of 2.55 and a beta of 1.01. Hologic, Inc. has a 52 week low of $64.02 and a 52 week high of $84.28.

Hologic (NASDAQ:HOLXGet Free Report) last released its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.05. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a net margin of 11.78% and a return on equity of 18.91%. Hologic’s quarterly revenue was down .8% compared to the same quarter last year. During the same quarter last year, the firm earned $1.06 EPS. As a group, analysts anticipate that Hologic, Inc. will post 4.08 earnings per share for the current year.

About Hologic

(Free Report)

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Read More

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLXFree Report).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.